DaVita Healthcare Partners Sued in GranuFlo® Cardiac Arrest Lawsuits
Four class action lawsuits have been filed in the United States District Court for the District of Colorado against DaVita Healthcare Partners, Inc., a company that provides dialysis services to patients with kidney failure and end stage renal disease. The suits allege that operators should have known about the potential for alkali dosing errors associated with GranuFlo® and NaturaLyte®, which are used during dialysis treatments. Alkali dosing errors can contribute to elevated bicarbonate levels, which in turn can lead to cardiac arrest, stroke, and sudden death.
The suits against DaVita are only the latest in a series of actions involving the drug GranuFlo®. Most GranuFlo® lawsuits have been targeting the drug’s manufacturer, Fresenius Medical Care, for failure to alert non-Fresenius dialysis clinics of the potential risks of alkai dosing errors. The dangers of GranuFlo® were not known outside of Fresenius until an internal memo was leaked to the FDA, which resulted in the issuance of a Class I Recall of the drug in March 2012.
As of May 2013, 161 GranuFlo® lawsuits were pending in a consolidated Multi-District Litigation proceeding in the United States District Court for the District of Massachusetts (MDL No. 2428). If you or a loved one has experienced adverse health effects from GranuFlo®, contact the experienced pharmaceutical attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297. We will confidentially evaluate your case for free and without any obligation.
Legal Disclaimer: The choice of a lawyer is an important decision and should not be based solely on advertisements.